A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. by Evangelou, Evangelos et al.
A meta-analysis of genome-wide association studies identifies novel variants associated with 
osteoarthritis of the hip.  
Supplementary Material 
Content 
1. Supplementary Methods 
a. Genotyping, data QC, data imputation 
b. Statistical analysis 
c. Study participants 
d. De novo genotyping for imputed SNPs rs6094710 and rs640070 
e. Heritability of the identified markers of hip OA 
2. Supplementary Figures 
a. Manhattan plots 
b. Q-Q plots  
c. Forest plots 
3. Supplementary Tables 
4.  Acknowledgements 
 1. Supplementary Methods 
a. Genotyping, data quality control and data imputation 
To allow for meta-analysis across different marker sets, imputation of polymorphic HapMap European CEU SNPs 
was performed using MACH or IMPUTE [1]. Two research centres (Ioannina, Greece and Erasmus MC Rotterdam, 
the Netherlands) performed both the Quality Control (QC) and meta-analyses. A QC protocol was set up including 
validation of the results file format, reports for range of values and elimination of potential biases (i.e., extremely large 
beta’s or SEs). Files were cross-validated between the two research centers after QC and after meta-analyses to check 
for inconsistencies. SNPs with a MAF <1%, imputation quality <0.30 (MACH) or <0.40 (IMPUTE) and beta’s >4 or 
<-4 were excluded for further analysis. 
b. Statistical analysis 
The principal summary measure of association was the per-allele odds ratio (OR). We performed genomic control at 
the individual study level estimates; for each study, we recorded the inflation factor lambda for the study so as to 
adjust the standard error of the effect size (standard error is multiplied by the square root of lambda). 
We summarized OR estimates using fixed-effects models [2]. Fixed-effects models assume that there is a common 
underlying effect and the variability observed is attributed to chance alone; random effects models acknowledge that 
true between-study heterogeneity exists, take into account the presence of heterogeneity into their calculations and, in 
the presence of heterogeneity, yield more conservative estimates. In the absence of heterogeneity, fixed- and random-
effects models yield the same results. Fixed-effects models are more appropriate at the SNP discovery and 
prioritization stage and perform well at the replication stage. The presence of statistically significant heterogeneity 
was assessed by the Q statistic (significant at p <0.10) and the extent of the observed heterogeneity was assessed by 
the I2 (ranging from 0% to 100%) [3]. We also summarized OR estimates under a random-effects model proposed by 
Han and Eskin [4]. 
 c. Study participants 
The Rotterdam Study I, II, & III:  The study population comprises men and women aged 55 years and older of the 
Rotterdam Study, which is a prospective population-based study on determinants of chronic disabling diseases. It 
consists of three sub-popualtions and the rationale and study design have been described previously [5]. The medical 
ethics committee of Erasmus University Medical School approved the study and written informed consent was 
obtained from each participant. Hip OA cases were defined as a KL grade≥2 or total hip replacement. 
deCODE: a list of patients with OA of hip was obtained on the basis of patients’ records at hospitals and health care 
centers in Iceland [6]. Controls were individuals with no external signs of OA in any joint who did not have a 
diagnosis of primary OA. The study was approved by the Data Protection Authority of Iceland and the National 
Bioethics Committee of Iceland. Informed consent was obtained from all participants. 
TwinsUK: the study participants were white monozygotic and dizygotic twin pairs from the TwinsUK adult twin 
registry, a group used to study the heritability and genetics of age-related diseases [7]. These unselected twins were 
recruited from the general population through national media campaigns in the United Kingdom. Ethics approval was 
obtained from the Guy’s and St. Thomas’ Hospital Ethics Committee. Written informed consent was obtained from 
every participant.  
The Genetics OsteoArthritis and Progression (GARP) study from Leiden, the Netherlands, consisted of 192 sibling 
pairs concordant for clinical and radiographically (K/L score) confirmed OA at two or more joint sites among hand, 
spine (cervical or lumbar), knee or hip [8], random controls (N=758) were partners of the offspring of the Leiden 
longevity study [9]. To comply with the discovery sample OA phenotypes for knee, hip and hand OA used were based 
on radiographic signs OA Written informed consent was obtained from each subject as approved by the ethical 
committees of the Leiden University Medical Center.  
arcOGEN study 
arcOGEN stage 1: The arcOGEN case samples were collected in two stages.  The stage 1 samples comprised 1,728 
hip cases from existing DNA collections from five United Kingdom locations within the arcOGEN consortium 
(London, Nottingham, Oxford, Sheffield, and Southampton). The detailed characteristics of these cases are described 
elsewhere [10]. Briefly, all were unrelated and of European origin, and all had primary OA of the hip of radiographic 
Kellgren-Lawrence (KL) grade ≥2, or clinical evidence of disease to a level requiring total joint replacement (TJR). 
The stage 1 study used 4,894 population-based UK controls from an early release of the Wellcome Trust Case Control 
Consortium 2 (WTCCC2) data which came from 2 distinct sources: the 1958 Birth Cohort [58BC] and the UK Blood 
Donor Service (UKBS) and were unrelated (www.wtccc.org.uk). 
arcOGEN stage 2: The stage 2 cases (n=1,763 with hip OA) were collected prospectively as part of the arcOGEN 
study at nine locations across the UK (Edinburgh, London, Newcastle-Upon-Tyne, Nottingham, Oxford, Sheffield, 
Southampton, Wansbeck, and Worcester) [11]. The ascertainment criterion was primary OA that was severe enough 
for the individual to require joint replacement of the hip. All cases were unrelated and of European origin. The 
controls (n=6,157) were population-based, unrelated UK controls which came from five distinct sources: the 1958 
Birth Cohort from the Type 1 Diabetes Genetics Consortium (T1DGC) study, the Avon Longitudinal Study of Parents 
and Children (ALSPAC), the People of the British Isles (PoBI) study and additional controls from the 58BC and the 
UKBS from the WTCCC2 study that were not overlapping with those used in stage 1.  
arcOGEN plus: The arcOGEN plus dataset (n=223 females with hip OA) comprises additional cases collected in 
stage 2 which were genotyped at a later stage. The ascertainment criterion was primary OA that was severe enough for 
the individual to require joint replacement of the hip. Controls (n=1,828) were unrelated, OA-free controls (females 
only) from the TwinsUK cohort which consist of twins ascertained to study the heritability and genetics of age-related 
diseases (www.twinsUK.ac.uk). Samples that overlapped with the TwinsUK dataset used in the discovery analysis 
were excluded from this study. 
Estonian Genome Center, University of Tartu (EGCUT). The Estonian cohort is from the population based 
biobank of the Estonian Genome Project of University of Tartu. The whole project is conducted according to the 
Estonian Gene Research Act and all participants have signed the broad inform consent. The current cohort size is over 
51,515, from 18 years of age and over, which reflects closely the age distribution of the adult Estonian population. 
Subjects were recruited randomly when visiting general practitioners (GPs) and hospitals. Each participant filled out a 
Computer Assisted Personal interview during 1-2 hours at doctors; office, including personal data. OA was diagnosed 
by a specialist as a clinical finding and was usually confirmed by a radiograph (KL grade>2). The OA cases for the 
current study had an ICD10 M16 and/or M17 diagnosis.  
Greek case-control study: The individuals included in the study were of Greek origin living in the district of 
Thessalia in central Greece [12]. All of them had undergone a TKR/THR, meaning that all of them suffered from 
severe knee or hip OA, which is defined by a K/L grade >=2. None of the patients had evidence of arthritis due to 
another disease. All the controls had a K/L score of 0 and had undergone treatment for injuries or fractures. Patients 
with rheumatoid arthritis and other autoimmune diseases as well asmchondrodysplasias, infection-induced OA, and 
posttraumatic OA were not included in the study. The ethics committee of the Larissa University Hospital approved 
this study and all individuals gave their informed consent.  
Spanish TJR cases: Patients were selected from consecutive patients, aged 55-75 years of age at time of the surgery, 
undergoing THR/TKR [13]. All patients were included if a rheumatologist considered them to suffer from severe 
primary OA. Exclusion criteria were inflammatory, infectious, traumatic or congenital joint pathology and lesions due 
to crystal deposition or osteonecrosis. Controls were recruited among subjects older than 55 years of age undergoing 
preoperative work-up for elective surgeries other than joint surgery and who did not show clinical manifestations of 
OA. This study was approved by the Ethical Committee for Clinical Research of Galicia and all cases and controls 
gave their written informed consent to participate.  
Swedish Malmo Diet and Cancer (MDC) study: All men and women living in the city of Malmö in Sweden, who 
were born between 1923 and 1945 (men) or between 1923 and 1950 (women) were invited to participate in the Malmö 
Diet and Cancer (MDC) study. The screening examination was performed during 1991-1996. All participants 
(n=28449) were followed until first OA surgery, emigration from Sweden, death or December 31 2005, whichever 
came first. Hip osteoarthritis was defined as a first hip arthroplasty (procedures coded 8414, 8010, NFB09, NFB19, 
NFB29, NFB39, NFB49 and NFB99) in combination with a contemporaneous diagnosis of hip osteoarthritis (715 or 
M16 according to ICD-9 and ICD-10, respectively). Cases were matched (1:1) for age, gender and BMI, to MDC 
participants without THR in a nested case-control design. 
Osteoporotic Fractures in Men Study (MrOS): The Osteoporotic Fractures in Men Study (MrOS) is a multi-center 
prospective, longitudinal, observational study of risk factors for vertebral and all non-vertebral fractures in older men, 
and of the sequelae of fractures in men [14,15].  The original specific aims of the study include: (1) to define the 
skeletal determinants of fracture risk in older men, (2) to define lifestyle and medical factors related to fracture risk, 
(3) to establish the contribution of fall frequency to fracture risk in older men, (4) to determine to what extent 
androgen and estrogen concentrations influence fracture risk, (5) to examine the effects of fractures on quality of life, 
(6) to identify sex differences in the predictors and outcomes of fracture, (7) to collect and store serum, urine and 
DNA for future analyses as directed by emerging evidence in the fields of aging and skeletal health, and (8) define the 
extent to which bone mass/fracture risk and prostate diseases are linked. The MrOS study population consists of 5,994 
community dwelling, ambulatory men aged 65 years or older from six communities in the United States (Birmingham, 
AL; Minneapolis, MN; Palo Alto, CA; Monongahela Valley near Pittsburgh, PA; Portland, OR; and San Diego, CA). 
Inclusion criteria were designed to provide a study cohort that is representative of the broad population of older men. 
The inclusion criteria were: (1) ability to walk without the assistance of another, (2) absence of bilateral hip 
replacements, (3) ability to provide self-reported data, (4) residence near a clinical site for the duration of the study, 
(5) absence of a medical condition that (in the judgment of the investigator) would result in imminent death, (6) ability 
to understand and sign an informed consent, and (7) 65 years or older. To qualify as an enrollee, the participant had to 
provide written informed consent, complete the self-administered questionnaire (SAQ), attend the clinic visit, and 
complete at least the anthropometric, DEXA, and vertebral X-ray procedures. The MrOS cohort recruited only men. 
Study of Osteoporotic Fractures (SOF): The Study of Osteoporotic Fractures (SOF) is a prospective multicenter 
study of risk factors for vertebral and non vertebral fractures[16].  The cohort is comprised of 9704 community – 
dwelling women 65 years old or older recruited from populations-based listings in four U.S. areas: Baltimore, 
Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania.  Women enrolled 
in the study were 99% Caucasian with African American women initially excluded from the study due to their low 
incidence of hip fractures. A cohort of AA women was recruited at the 6th Visit. The SOF participants were followed 
up every four months by postcard or telephone to ascertain the occurrence of falls, fractures and changes in address. 
To date, follow-up rates have exceeded 95% for vital status and fractures. All fractures are validated by x-ray reports 
or, in the case of most hip fractures, a review of pre-operative radiographs. The inclusion criteria were: 1) 65 years or 
older, (2) ability to walk without the assistance of another, (3) absence of bilateral hip replacements, (4) ability to 
provide self-reported data, (5) residence near a clinical site for the duration of the study, (6) absence of a medical 
condition that (in the judgment of the investigator) would result in imminent death, and (7) ability to understand and 
sign an informed consent. To qualify as an enrollee, the participant had to provide written informed consent, complete 
the self-administered questionnaire (SAQ), attend the clinic visit, and complete at least the anthropometric measures. 
The SOF study recruited only women 
Paprika study: The Paprika study is performed at the Leiden University Medical Center (Dept. Orthopedics) and 
consists in a long-term follow-up study of patients that have undergone total joint replacement (TJR) at hip or knee 
[17-19] and has been approved by the medical ethical committee. Patients of Caucasian descent were included when 
they were diagnosed with primary osteoarthritis based on radiographs and the ACR rheumatology classification 
criteria (mean age males-hip: 66; years males-knee: 68 years; females-hip: 66 years; females-knee: 69 years). Patients 
with secondary OA or requiring a revision were excluded in this study. Written consent was obtained from each 
participant. 
Genotyping. 
The Rotterdam Study I, II & III: Genotyping of the samples with the Illumina HumanHap550v3 Genotyping 
BeadChip was carried out at the Genetic Laboratory of the Department of Internal Medicine of Erasmus Medical 
Center, Rotterdam, the Netherlands. The Beadstudio GenCall algorithm was used for genotype calling and quality 
control procedures were as described previously [20]. The following quality control filters were applied: SNP call rate 
>= 95%, minor allele frequency >= 5%, p-value HWE >=1x10-6. After quality control 500,510 SNPs remained for 
association analyses. The intensity cluster plots were visually inspected for the top-hits of the Rotterdam Study and no 
abnormalities were discovered. Genomic inflation factors were calculated for all analyses and there was no evidence 
of population stratification with lambdas of 1.01 for hip- and hand-OA, 1.00 for knee-OA 
deCODE: All samples were assayed with the Infinium HumanHap 300 or humanCNV370 SNP chips (Illumina), 
containing 317,503 tagging SNPs derived from phase I of the International HapMap project. All of the SNPs tested in 
this report passed quality filtering (a call rate >97%, a minor allele frequency >1%, not a significant distortion from 
HWE (p-value >10-7 on any of the three chip types used (humanHap300, humanHap300-duo and humanCNV370). 
Any samples with a yield <98% were excluded from the analysis. Imputation was done using the IMPUTE software 
[1]. The additional cases in the replication analysis were genotyped using the Centaurus (Nanogen) platform 
TwinsUK: Samples were genotyped with the Infinium HumanHap 300 assay (Illumina, San Diego, USA) at the Duke 
University Genotyping Center (NC USA), Helsinki University (Finland) and the Wellcome Trust Sanger Institute. The 
Illuminus calling algorithm was used for genotype calling. After strict quality control criteria were applied as 
described in [20] there were 314075 SNPs available for analysis. Imputation was performed using the IMPUTE 
software (v0.2.0) [1].  At imputed loci, all genotypes with posterior probabilities < 0.9 were discarded and the imputed 
loci were filtered out using usual QC filters. 
Genetics OsteoArthritis and Progression (GARP) Study: For the GARP study the genome wide scan was 
genotyped by Illumina Infinuum II HumanHap 55KL Beadchips and Illumina Infinium II HumanHap550-Duo 
BeadChips (Illumina, San Diego, USA), respectively. Genotypes from the SNPs from the HapMap phase II v21 were 
imputed using IMPUTE.   
arcOGEN study: arcOGEN stage 1 and stage 2 cases were genotyped using Illumina Human 610-Quad BeadChips.  
The publically available controls used for stage 1 and for stage 2 were genotyped on a variety of platforms (Table 1) 
[10,11]. ArcOGEN plus cases were genotyped on the Illumina HumanOmniExpress platform. This study used 
TwinsUK disease-free controls which were genotyped on Illumina Human 610-Quad BeadChips. All datasets 
underwent QC at the sample and SNP level separately for each case and control cohorts as previously [10,11]. Briefly 
samples were excluded if their call rate was <97% and if they showed gender discrepancies (estimated from genotypic 
data against external information). Individuals were also excluded on the basis of excess genome-wide heterozygosity 
or homozygosity. We identified samples that were accidentally duplicated or closely-related by calculating genome-
wide IBD (given IBS information) for pairs of individuals. Multidimensional scaling (MDS) was performed in 
conjunction with data from the three HapMap phase II populations in order to identify and exclude individuals of non-
European descent. SNPs were excluded from further analysis based on the following criteria: Call rate <95% if minor 
allele frequency (MAF)≥5% or call rate <99% if MAF<5%, HWE exact p values <0.0001 in cases or controls, and 
MAF <1%. Association analyses were carried out under the additive model. Imputation was carried out using 
IMPUTE and imputed genotypes were analysed taking under account the full genotype probability distribution. 
Osteoporotic Fractures in Men Study (MrOS) and Study of Osteoporotic Fractures (SOF): The Illumina 
HumanOmni1_Quad_v1-0 B was used for whole-genome genotyping. Samples from SOF and MrOS were 
randomized to 96-well genotyping plates by sex and clinic site. Eighty-one samples were plated twice to assess 
reproducibility. Pairwise concordance was 100%. 119 replicates of samples from HapMap trios of CEU and YRI 
populations and singletons from CHB and JPT populations were genotyped alongside MrOS and SOF samples, and 
compared to published HapMap genotypes. Concordance was 99.7% for CEU and YRI samples and was 95.0-99.7%  
for CHB and JPT samples. Genotypes were called using a clustering algorithm in Illumina’s BeadStudio software at 
the Broad Institute. Samples with call rates < 97% were excluded. SNPs with GenTrain scores <0.6, cluster separation 
scores <0.4, call rates <97%, or MAF <0.01 were excluded. Autosomal SNPs with HWE P-value <10-4 were excluded. 
In addition, genotype clusters for SNPs on chrX, chrY, chrXY and chrMT were reviewed manually.  For MrOS and 
SOF samples, 740,713 SNPs passed QC.Additional samples were excluded based on: (1) genotypic sex mismatch 
using X and Y chromosome probe intensities, (2) relatedness among genotyped samples using the kinship coefficient 
that estimates probability that alleles are identical-by-descent, and (3) gross chromosomal abnormalities detected 
using the LogR Ratio and B allele frequency. Among the 3924 SOF samples that underwent whole-genome 
genotyping, 3682 samples had acceptable call rates.  Among these 3682 SOF samples, 4 were removed due to 
relatedness and 53 were removed due to gross chromosomal abnormalities, leaving 3625 SOF samples with whole 
genome genotyping data that passed QC. Among the 5506 MrOS samples that underwent whole-genome genotyping, 
5189 samples had acceptable call rates. Among these 5189 MrOS samples, 1 was removed due to relatedness and 37 
were removed due to gross chromosomal abnormalities, leaving 5151 MrOS samples with whole genome genotyping 
data that passed QC. SNPs and samples that passed QC filters underwent SNP genotype imputation using minimac.  
HapMap phase II release 22 build 36 consensus phased haplotypes from a combined panel of CEU, YRI, CHB, and 
JPT HapMap samples were used as a reference panel 
Estonian Genome Center, University of Tartu (EGCUT). All samples were genotyped with Illumina 
HumanCNV370 or HumanOmniExpress (Illumina, San Diego, USA) according to the Illumina protocol in the 
Estonian Biocenter. Data quality control was perform with PLINK (SNP call rate>98%;sample call rate>95%; 
MAF>0.01; HWE p>10-6; cryptic relatedness). Imputation was performed with IMPUTE v1.0 (CEU HapMap rel22 
build 36) and association analyses were carried out with SNPTEST. Inflation factors for directly genotyped and 
imputed data were 1.01 and 1.01 respectively. 
Paprika study: In the present work, genotyping of the Paprika study was performed using the Sequenom 
MassARRAY iPLEX Gold or Taq-Man SNP Genotyping assays following the manufacturer’s instructions. All SNPs 
passed the following quality criteria: call rate >98% and p-value for Hardy-Weinberg equilibrium <10-4. 
 
 
d. De novo genotyping for imputed SNPs rs6094710 and rs640070 
Imputed SNPs rs6094710 and rs640070 had MAF <4% and even though they passed the imputation quality criteria set 
upfront therefore they were de novo genotyped to minimize the possibility of imputation errors. Random samples of 
three populations from TWINS UK (n=392), arcOGEN (n=1046) and Rotterdam (n=865) were used for the 
assessment. For rs6094710 the concordance was 97.7%, 98.9% and 99.1% respectively.  Poor concordance was found 
for rs640070 (<60% in all cases) and therefore it was excluded from further consideration. 
e. Heritability of the identified markers of hip OA 
We searched Pubmed for variants that have been identified as susceptible for hip OA in European populations. Only 
articles in English were eligible. We retrieved the hits that were GWS (P<5x10-8) or reported as suggestive signals by 
the authors of the studies. From each study we recorded the study, the eligible variant, the risk allele frequency and the 
OR. We then calculated the sibling recurrence risk ratio attributed to these markers by using the formula 
λs = 1+
pq γ −1( )2
2 p + γq( )2
 
 
 
 
 
 
 
 
2
where q is the risk allele frequency, p=1-q, γ=genotype relative risk under the log-additive 
model. The expected genetic variance explained was calculated as described in Ju-Hyun P et al [21]
  
 
 
2. Supplementary figures 
 
FIGURE LEGENDS 
Figure S1: Manhattan plot for the combined analysis of the hip OA GWAs meta-analysis. 
 
Figure S2: QQ plot for the combined analysis of the hip OA GWAs meta-analysis.  The expected p-value is 
indicated by the solid line and the associated 95% confidence intervals are indicated by the blue area either 
side  
 
Figure S3: QQ plot for the A) female-specific and B) male-specific analysis of the hip OA GWAs meta-
analysis. The expected p-value is indicated by the solid line and the associated 95% confidence intervals are 
indicated by the blue area either side  
 
Figures S4-S11: Forest plots for the 8 SNPs that were followed-up in the 2nd stage of the analysis. The blue 
diamond denotes the summary effect size and its edges the respective 95% confidence intervals. Studies 
shaded in blue were included in the replication stage. * Discovery and replication estimate combined. 
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3. Supplementary Tables 
 Table S1. Summary statistics for cases and controls in the groups that were included in the discovery stage. 
Study N 
cases 
Females 
(%) 
Age 
Mean (SD) 
BMI 
Mean (SD) 
Height 
Mean (SD) 
N 
controls 
Females 
(%) 
Age 
Mean (SD) 
BMI 
Mean (SD) 
Height 
Mean (SD) 
Discovery           
arcOGEN 1728 64 65.8 (8.7) 28.1 (5.4) 165 (9.0) 4896 49.0 NA NA NA 
deCODE 1423 55 69.7 (7.7) 26.8 (4.5) 169 (9.0) 31385 55 51.3 (21.7) 27.1 (5.3) 170 (9.0) 
EGCUT 64 74 71.7 (13.2) 29.5 (4.6) 164.8 (9.2) 2531 56 47.4 (2.2) 25.7 (5.7) 164.3 (6.9) 
GARP 106 82 60.1 (7.6) 26.8 (5.4) 168.0 (7.8) 1671 55 57.7 (1.4) 26.2 (5.5) 169.9 (9.3) 
RSI 760 53 67.4 (7.7) 26.0 (3.5) 168.0 (9.3) 3233 51 66.9 (7.6) 25.8 (3.4) 168.3 (9.3) 
RSII 159 52 64.0 (7.5) 27.0 (4.0) 169.1 (9.3) 1472 51 63.4 (6.9) 26.9 (4.0) 169.3 (9.3) 
RSIII 41 56 55.7 (5.4) 27.3 (4.3) 171.2 (9.3) 1487 56 55.6 (5.4) 27.3 (4.3) 171.1 (9.4) 
TwinsUK 68 100 56.2 (7.8) 26.0 (4.6) 161.0 (6.3) 228 100 49.0 (5.9) 24.3 (4.0) 162.4 (5.8) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Association p-values of the prioritized SNPs before and after adjustments for age, BMI and height 
 
SNP/Group P Unadjusted P Age-Adjusted P BMI-Adjusted P Height-Adjusted 
rs6094710 
arcOGEN 0.0003398 NA NA NA 
deCODE 0.013 0.028 0.029 0.026 
EGCUT 0.226229 0.448463 0.236926 0.379193 
GARP 0.42634 0.665 0.407 0.461 
RSI 0.01931 0.0142 0.0157 0.01757 
RSII 0.03662 0.04299 0.03607 0.02804 
RSIII 0.6377 0.49 0.6325 0.499 
TWINSUK 0.81883 0.9473 0.5693 0.5272 
rs1577792 
arcOGEN 0.0026362 NA NA NA 
deCODE 0.014 0.017 0.017 0.02 
EGCUT 0.592781 0.437926 0.52881 0.526826 
GARP 0.18416 0.474 0.223 0.254 
RSI 0.001447 0.014 0.001551 0.001623 
RSII 0.03931 0.07495 0.03963 0.03916 
RSIII 0.8852 0.858 0.8509 0.7973 
TWINSUK 0.36496 0.9349 0.332 0.2965 
rs5009270 
arcOGEN 0.01702 NA NA NA 
deCODE 0.0024 0.0023 0.015 0.014 
EGCUT 0.0323308 0.0276716 0.0386288 0.0366348 
GARP 0.027003 0.041 0.062 0.053 
RSI 0.004403 0.002941 0.004449 0.004 
RSII 0.4895 0.508 0.479 0.4734 
RSIII 0.1292 0.2191 0.1215 0.3647 
TWINSUK 0.63171 0.7448 0.8074 0.8516 
rs10773046 
arcOGEN 0.0015225 NA NA NA 
deCODE 0.0000194 0.0000125 0.00029 0.00036 
EGCUT 0.756363 0.989485 0.77615 0.831619 
GARP 0.47104 0.274 0.367 0.404 
RSI 0.6551 0.5028 0.6319 0.6769 
RSII 0.1994 0.3065 0.1791 0.1978 
RSIII 0.4235 0.1293 0.4174 0.1927 
TWINSUK 0.30965 0.4033 0.3059 0.1895 
rs17610181 
arcOGEN 0.0034746 NA NA NA 
deCODE 0.57 0.92 0.3 0.33 
EGCUT NA 0.0549912 0.146748 0.168055 
GARP 0.084506 0.085 0.089 0.103 
RSI 0.000087 0.0001067 0.000216 0.1851 
RSII 0.03551 0.03559 0.03916 0.0302 
RSIII 0.5777 0.6116 0.1849 0.1398 
TWINSUK 0.91205 0.6116 0.7059 0.6352 
rs10878630 
arcOGEN 0.0282 NA NA NA 
deCODE 0.00014 0.00029 0.0000429 0.0000365 
EGCUT 0.0125402 0.0722638 0.0460731 0.0821358 
GARP 0.4427 0.182 0.431 0.451 
RSI 0.5189 0.5768 0.4333 0.5768 
RSII 0.1499 0.1465 0.1564 0.1465 
RSIII 0.1882 0.1864 0.1849 0.1854 
TWINSUK 0.23472 0.4759 0.2289 0.1637 
rs12551314 
arcOGEN 0.0096 NA NA NA 
deCODE 0.0028 0.0026 0.00044 0.00089 
EGCUT 0.962784 0.562756 0.539139 0.659855 
GARP NA 0.705 0.271 0.259 
RSI 0.06476 0.05551 0.248 0.06039 
RSII 0.1507 0.1674 0.135 0.1449 
RSIII 0.001947 0.0009252 0.001961 0.001217 
TWINSUK NA NA NA NA 
rs3757837 
arcOGEN 0.03802 NA NA NA 
deCODE 0.0000122 0.0000234 0.0000243 0.0000381 
EGCUT 0.38955 0.203123 0.104614 0.562756 
GARP NA 0.197 0.256 0.296 
RSI 0.2497 0.1901 0.2607 0.242 
RSII 0.7047 0.8979 0.7049 0.7067 
RSIII 0.01069 0.00433 0.005202 0.005141 
TWINSUK NA NA NA NA 
 
 
Table S3. Association p-values of the prioritized SNPs in publicly available databases of height and BMI 
  Height BMI 
Marker Locus P # individuals P # individuals 
rs6094710 20q13 0.092 131389 0.96 123206 
rs1577792 6q14 0.66 133766 0.046 123861 
rs5009270 7q31 0.27 127727 0.63 119547 
rs10773046 12q24 2.1E-04 133828 0.42 123863 
rs17610181 17q23 0.70 132978 0.13 123864 
rs10878630 12q15 0.55 133647 1.00 123718 
rs12551314 9q22 0.30 133762 0.65 123866 
rs3757837 7p13 0.46 116897 0.81 116638 
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